Ozoralizumab
As of the edition of 20 October 2026, Ozoralizumab is an antibody: marketed, first approved in 2022 (JP); acts on TNF.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2022
- Kind
- Antibody
- Brand name
- Nanozora
- First approved
- 26 September 2022 (JP)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Taisho Pharmaceutical
- Registered trials
- 4, 0 stopped early
- Disease areas
- Bones, joints and muscles; Immune system; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TNF | Tumor necrosis factor | P01375 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 4 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Taisho Pharmaceutical | Applicant and Lead sponsor of trials | 2019 to now |